Does Bimzelx Treat Psoriasis?
Bimzelx (bimekizumab-bkzx) is FDA-approved for moderate-to-severe plaque psoriasis in adults who qualify for systemic therapy or phototherapy. It targets IL-17A and IL-17F, cytokines driving psoriasis inflammation, reducing plaques, scaling, and itching. In phase 3 trials (BE READY, BE VIVID, BE RADIANT), 85-91% of patients achieved PASI 90 (90% skin clearance) by week 16, versus 7-22% on placebo. About 60% reached PASI 100 (complete clearance).[1][2]
How Quickly Does Bimzelx Work for Psoriasis?
Patients see improvements within 4 weeks, with rapid reductions in symptoms. In trials, 40-50% hit PASI 75 by week 4, building to peak efficacy by week 16. Long-term data shows sustained response through 144 weeks with 320 mg every 8 weeks after initial loading doses.[1]
Bimzelx vs. Other Psoriasis Biologics
| Drug | Targets | PASI 90 at Week 16 | Dosing Frequency |
|------|---------|---------------------|------------------|
| Bimzelx | IL-17A/F | 85-91% | Every 4-8 weeks |
| Cosentyx (secukinumab) | IL-17A | 70-80% | Every 4 weeks |
| Taltz (ixekizumab) | IL-17A | 70-80% | Every 4 weeks |
| Skyrizi (risankizumab) | IL-23 | 75-85% | Every 12 weeks |
Bimzelx matches or exceeds single-IL-17 blockers on clearance rates and offers less frequent dosing than IL-17A drugs after loading. Against IL-23 inhibitors, it provides faster onset but similar long-term results. No head-to-head trials exist.[1][3]
Who Can't Use Bimzelx for Psoriasis?
Not for mild psoriasis, children under 18, or active infections (e.g., TB). Contraindicated with live vaccines. Avoid in Crohn's disease history due to IL-17 risks. Pregnancy data limited; use weighs benefits vs. fetal risks.[2]
Common Side Effects and Risks
Upper respiratory infections (15-20%), oral candidiasis (7-14%, due to IL-17 role in antifungal defense), and injection-site reactions (4-8%) occur most. Serious risks include hypersensitivity and IBD flares (rare, <1%). Monitor for infections; no increased malignancy signal in trials.[1][2]
Cost and Access for Psoriasis Patients
List price ~$6,000/month (320 mg dose). Patient assistance via UCB's program caps copays at $5/month for eligible insured patients. Biosimilars unlikely before 2033 due to patents.[4]
[1]: FDA Bimzelx Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761195s000lbl.pdf
[2]: NEJM Phase 3 Trials (BE READY/BE VIVID) - https://www.nejm.org/doi/full/10.1056/NEJMoa2109539
[3]: Lancet Comparison Review - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01234-5/fulltext
[4]: DrugPatentWatch - https://www.drugpatentwatch.com/p/tradename/BIMZELX